Run rare-disease variant prioritization pipelines on trio/quad WES/WGS: cascade filters (QC, population frequency, functional consequence, inheritance), call de novo variants (DeNovoGear, Triodenovo, DeNovoCNN) with IGV review, phase compound heterozygotes (WhatsHap), rank by phenotype concordance (Exomiser hiPHIVE, Phen2Gene, AMELIE), gate by ClinGen gene-disease validity, and flag ACMG SF v3.2 (Miller 2023; 81 genes). Variant classification (PVS1 decision tree, Pejaver 2022 PP3/BP4 thresholds, Tavtigian point system) is deferred to clinical-databases/acmg-classification.
pip install cyvcf2 pyhgvs pandas myvariant
# De novo callers
conda install -c bioconda denovogear
# Triodenovo: https://genome.sph.umich.edu/wiki/Triodenovo
# DeNovoCNN: https://github.com/Genomics-CISDC/DeNovoCNN
# Phenotype-driven
# Exomiser: https://www.sanger.ac.uk/tool/exomiser/
# Phen2Gene: pip install phen2gene
# AMELIE: https://amelie.stanford.edu/
# Compound het phasing
conda install -c bioconda whatshap
# HPO + ClinGen
# Download HPO: wget http://purl.obolibrary.org/obo/hp.obo
# ClinGen validity: https://search.clinicalgenome.org/kb/gene-validity
Tell the agent what to do: - "Run rare-disease prioritization on this trio WES VCF; output ranked candidates by inheritance pattern" - "Identify de novo candidates with DeNovoGear; flag for IGV review" - "For singleton WES, find compound heterozygous candidates with WhatsHap read-based phasing" - "Rank candidates by phenotype concordance via Exomiser hiPHIVE; HPO terms: HP:0001250, HP:0001263, HP:0000175" - "Cross-check candidates against ACMG SF v3.2 (81 genes, Miller 2023); flag CALM1/2/3 + other newly-added"
"Run full trio pipeline on this Mendelian-suspected family. Filter to grpmax_faf95 < 0.0001 (dominant) or 0.005 (recessive). Apply DeNovoGear; IGV-review reportable DNVs. Output ranked candidates with inheritance pattern."
"For trio with consanguineous parents, prioritize autosomal-recessive homozygous candidates; relax frequency to grpmax_faf95 < 0.01 for AR; cross-check ClinGen gene-disease validity (Moderate+)."
"Singleton WES, suspect AR; run WhatsHap read-based phasing for compound het candidates within 500 bp; flag for parental confirmation."
"Singleton from consanguineous proband; prioritize hom-alt + compound het in genes with ClinGen Moderate+ validity."
"DeNovoGear + IGV review on this trio. Posterior probability >= 0.9, parental coverage >= 10x, manual IGV review for all reportable DNVs."
"Flag candidate DNVs in tandem repeat regions, segmental duplications, or with parental coverage < 10x as low-confidence."
"Submit Exomiser hiPHIVE with 8 specific HPO terms for this patient. Top-5 ranks should capture diagnosis 94% (Cipriani 2020)."
"Run Phen2Gene as secondary ranking; compare top-5 to Exomiser. Manual review if discordant."
"For phenotype with sparse HPO, run GADO (HPO-free option) and AMELIE (literature-mining); cross-check."
"For each candidate variant, flag if gene is in ACMG SF v3.2 (Miller 2023; 81 genes). Note v3.2 additions: CALM1, CALM2, CALM3 (calmodulinopathies)."
"Generate separate SF-only report for opt-in disclosure; reportable only if P/LP per
acmg-classification."
"Patient has suspected mosaic PIK3CA / GNAS / NRAS disorder. Lower VAF threshold to 2-5%; require depth >= 200x; report affected tissue if available."
"Re-evaluate VUS labeled prior to 2022 in this active diagnostic variant list; cross-check Genome Alert! (Yauy 2022) for ClinVar changes; flag for re-curation."
clinical-databases/acmg-classification.clinical-databases/acmg-classification.clinical-databases/pharmacogenomics.